NASDAQ: SLNO - Soleno Therapeutics, Inc.

Rentabilität für sechs Monate: +42.58%
Sektor: Healthcare

Aktionsplan Soleno Therapeutics, Inc.


Über das Unternehmen

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.


EBITDA -0.0159
Число акций ао 0.01649 млрд
P/BV 6.24
EV/EBITDA -4.56
Цена ао 54.92
ISIN US8342033094
Сайт https://soleno.life
Валюта usd
IPO date 2014-11-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Preisänderung pro Tag: -1.12% (55.54)
Preisänderung pro Woche: +12.2% (48.95)
Preisänderung pro Monat: +13.05% (48.58)
Preisänderung über 3 Monate: +15.21% (47.67)
Preisänderung über sechs Monate: +42.58% (38.52)
Preisänderung pro Jahr: +124.44% (24.47)
Preisänderung über 3 Jahre: +5 840.51% (0.9245)
Preisänderung über 5 Jahre: +2 868.65% (1.85)
Preisänderung seit Jahresbeginn: +146.22% (22.305)

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 3.97 4
P/E 0 0
EV/EBITDA -12.41 0
Gesamt: 2.25

Effizienz

Name Bedeutung Grad
ROA, % -21.58 0
ROE, % -24.75 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.011 10
Gesamt: 8.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -51866.73 0
Rentabilität Ebitda, % 130.89 10
Rentabilität EPS, % -85.02 0
Gesamt: 3.6

Institutionen Volumen Aktie, %
Vivo Capital, LLC 8418093 25.93
Nantahala Capital Management, LLC 5712702 17.6
Perceptive Advisors LLC 3074542 9.47
Carlyle Group Inc. 2857804 8.8
Janus Henderson Group PLC 2523897 7.78
Adage Capital Partners GP L.L.C. 1826814 5.63
Vestal Point Capital, LP 1300000 4
Vanguard Group Inc 969622 2.99
Balyasny Asset Management LLC 926876 2.86
Avoro Capital Advisors LLC 785000 2.42

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares ESG Aware MSCI USA Small-Cap ETF 0.04862 31.110458284371 1.49366
iShares Morningstar Small-Cap ETF 0.02055 30.095066471445 1.60498
iShares Morningstar Small-Cap Growth ETF 0.04077 33.628071953382 0.72598
iShares Russell 2000 Growth ETF 0.08818 38.042556988 0.6026
iShares Russell 3000 ETF 0.00204 31.230028873917 1.43482
iShares Morningstar Small-Cap ETF 0.02055 391.25300933451 1.60498
iShares Morningstar Small-Cap Growth ETF 0.04077 682.83677107207 0.72598



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Anish Bhatnagar M.D. President, CEO, COO & Director 1.06M 1970 (54 Jahr)
Mr. James H. MacKaness Chief Financial Officer 640k 1964 (60 Jahre)
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development N/A
Ms. Kristen Yen M.S. Senior Vice President of Clinical Operations 317.19k 1969 (55 Jahre)
Ms. Meredith Manning M.B.A. Chief Commercial Officer N/A 1972 (52 Jahr)
Ms. Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs 493k 1966 (58 Jahre)
Ms. Lauren Budesheim Vice President of People N/A
Dr. Michael Huang M.D. Senior Vice President of Clinical Development N/A 1974 (50 Jahre)
Dr. Raymond W. Urbanski M.D., Ph.D. Chief Development Officer 1959 (65 Jahre)

Adresse: United States, Redwood City. CA, 203 Redwood Shores Parkway - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://soleno.life